Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-03-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a shareholder of the company. It details the shareholder's name, number of shares released from pledge, pledge start and release dates, pledgee, and reasons for release. There is no financial data, no mention of financial results, no management discussion, no meeting materials, or any other report type content. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledge status and does not fit into more specific categories like Major Shareholding Notification (MRQ) since it concerns pledge release rather than ownership threshold changes.
2019-03-29 Chinese
特定股东减持股份预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a specific shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number of shares held, the planned reduction amount, the method of reduction (block trade), timing, and related risk disclosures. There is no financial data, no discussion of company financial performance, no meeting materials, no voting results, no legal proceedings, and no mention of report publication. The document fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or planned share reductions by large shareholders.
2019-03-19 Chinese
关于BPI-23314片获得临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving a clinical trial notification from the National Medical Products Administration (NMPA) for a new drug. It details the approval to start clinical trials, the drug's characteristics, and associated risks. The document is short (1270 characters) and serves as an official announcement rather than a detailed report or financial filing. It does not contain financial data, management changes, or regulatory certifications. It is not an annual or interim report, earnings release, or any form of financial or governance report. It is a regulatory announcement about clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-03-18 Chinese
关于公司实际控制人增持计划实施期间届满并实施完毕的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a share increase plan by the company's actual controller and CEO, Ding Lieming. It details the number of shares increased, the period of the plan, legal opinions, and compliance with regulations. The document is relatively short (2252 characters) and focuses on the completion and disclosure of a shareholding increase by a major shareholder. It does not contain financial statements or detailed financial performance data. This fits the category of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. It is not a full financial report, earnings release, or regulatory filing of another type. Therefore, the appropriate classification is MRQ with high confidence.
2019-02-27 Chinese
2018年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2018 年度业绩快报' which translates to '2018 Annual Performance Express Report' or '2018 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2018, including revenue, profit, earnings per share, and asset information. The document explicitly states that the data is preliminary, unaudited, and that final audited data will be disclosed in the annual report. The length is 1846 characters, which is relatively short and the document is a summary of financial results rather than a full detailed report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is also not a Report Publication Announcement (RPA) because it contains actual preliminary financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2018
2019-02-27 Chinese
国浩律师（杭州）事务所关于公司实际控制人增持股份之法律意见书
Director's Dealing Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the actual controller of Betta Pharmaceuticals increasing their shareholding. It details the shareholding changes, legal compliance, and confirms the legality of the share acquisition. The document is a standalone legal opinion related to a director's or controlling shareholder's share transactions, not a general announcement or a financial report. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content fits the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). Therefore, the appropriate classification is DIRS (Director's Dealing).
2019-02-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.